Benefits
Lipid profile improvement
Multiple RCTs show spirulina reduces total cholesterol, LDL and triglycerides while modestly raising HDL. A meta-analysis of 7 RCTs found significant lipid lowering, though the trials were small and varied and the pooled effect did not increase with dose.
Anti-inflammatory (modest CRP effect)
Phycocyanin is an antioxidant pigment in laboratory tests. In pooled human trials, spirulina modestly lowered C-reactive protein, but had no significant effect on the oxidative-stress marker MDA and only a marginal, non-significant effect on IL-6.
Allergic rhinitis symptom relief (one trial)
In cell and animal studies, spirulina extracts activate macrophages and NK cells and raise IgA; the influenza and antiviral findings come from chickens and mice, not people. The only human immune-related trial is a single-center study in allergic rhinitis, where spirulina eased nasal symptoms.
Blood sugar regulation
A meta-analysis of 8 RCTs in type 2 diabetes found spirulina lowered fasting glucose, but it did not significantly change HbA1c or post-meal glucose. Effects on insulin sensitivity are proposed but not established.
Mechanism of action
Phycocyanin antioxidant activity
C-phycocyanin directly scavenges hydroxyl radicals, peroxyl radicals, and peroxynitrite with higher potency than most plant polyphenols. It also inhibits NADPH oxidase, a key source of cellular ROS.
NF-κB and COX-2 inhibition
Phycocyanin inhibits NF-κB nuclear translocation, reducing transcription of inflammatory mediators including COX-2, TNF-α, and IL-6.
Lipid metabolism modulation
Spirulina upregulates LDL receptor expression in hepatocytes, increases bile acid synthesis from cholesterol, and may inhibit intestinal cholesterol absorption.
Clinical trials
Pooled analysis of 7 clinical trials examining spirulina supplementation on lipid parameters.
522 participants across 7 clinical trials.
Pooled across 7 randomized trials, spirulina lowered total cholesterol by about 47 mg/dL, LDL by about 41 mg/dL and triglycerides by about 44 mg/dL, and raised HDL by about 6 mg/dL. The reduction grew with longer use but did not depend on dose, and the trials were small and varied.
Randomized trial in 25 people with type 2 diabetes: spirulina 2 g/day versus a non-placebo control group for 2 months.
25 people with type 2 diabetes. 2-month intervention.
Fasting and post-meal glucose, HbA1c and triglycerides fell over 2 months, with a small drop in total and LDL cholesterol. CRP was not measured. This is one small, non-blinded trial; a pooled meta-analysis of 8 trials found no significant HbA1c effect.